Name | Number of supported studies | Average coverage | |
---|---|---|---|
goblet cell | 9 studies | 51% ± 17% | |
respiratory goblet cell | 7 studies | 29% ± 10% | |
fibroblast | 7 studies | 26% ± 10% | |
club cell | 5 studies | 23% ± 11% | |
epithelial cell | 5 studies | 28% ± 11% | |
connective tissue cell | 5 studies | 31% ± 20% | |
type II pneumocyte | 4 studies | 24% ± 11% | |
oligodendrocyte precursor cell | 3 studies | 26% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
intestine | 3 studies | 21% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 6118.31 | 245 / 245 | 100% | 298.05 | 501 / 502 |
pancreas | 100% | 5391.41 | 328 / 328 | 90% | 123.50 | 161 / 178 |
stomach | 94% | 5662.05 | 336 / 359 | 90% | 164.69 | 258 / 286 |
intestine | 92% | 2566.35 | 888 / 966 | 87% | 138.63 | 461 / 527 |
breast | 93% | 1254.52 | 426 / 459 | 78% | 69.17 | 868 / 1118 |
lung | 93% | 1915.75 | 539 / 578 | 64% | 73.43 | 737 / 1155 |
bladder | 100% | 2895.05 | 21 / 21 | 51% | 37.00 | 255 / 504 |
uterus | 92% | 2025.99 | 157 / 170 | 39% | 34.88 | 178 / 459 |
ovary | 81% | 1172.72 | 145 / 180 | 47% | 21.99 | 204 / 430 |
esophagus | 52% | 435.83 | 748 / 1445 | 74% | 169.23 | 135 / 183 |
adrenal gland | 100% | 1955.27 | 258 / 258 | 13% | 8.00 | 30 / 230 |
heart | 99% | 1782.37 | 853 / 861 | 0% | 0 | 0 / 0 |
adipose | 86% | 970.24 | 1037 / 1204 | 0% | 0 | 0 / 0 |
thymus | 77% | 588.29 | 504 / 653 | 7% | 3.68 | 42 / 605 |
skin | 72% | 3053.34 | 1304 / 1809 | 8% | 5.02 | 39 / 472 |
blood vessel | 77% | 771.19 | 1025 / 1335 | 0% | 0 | 0 / 0 |
brain | 34% | 208.01 | 893 / 2642 | 20% | 7.75 | 139 / 705 |
kidney | 38% | 240.43 | 34 / 89 | 10% | 6.42 | 90 / 901 |
spleen | 45% | 322.15 | 108 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 22% | 8.80 | 10 / 45 |
peripheral blood | 10% | 104.26 | 95 / 929 | 0% | 0 | 0 / 0 |
liver | 4% | 24.66 | 8 / 226 | 6% | 4.85 | 24 / 406 |
muscle | 4% | 21.71 | 35 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 8.80 | 1 / 29 |
eye | 0% | 0 | 0 / 0 | 3% | 1.07 | 2 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1902236 | Biological process | negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_0034976 | Biological process | response to endoplasmic reticulum stress |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_1903671 | Biological process | negative regulation of sprouting angiogenesis |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0030968 | Biological process | endoplasmic reticulum unfolded protein response |
GO_0032967 | Biological process | positive regulation of collagen biosynthetic process |
GO_0070278 | Biological process | extracellular matrix constituent secretion |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0040037 | Biological process | negative regulation of fibroblast growth factor receptor signaling pathway |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0003682 | Molecular function | chromatin binding |
GO_0000976 | Molecular function | transcription cis-regulatory region binding |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0046332 | Molecular function | SMAD binding |
GO_0035497 | Molecular function | cAMP response element binding |
GO_0005515 | Molecular function | protein binding |
Gene name | CREB3L1 |
Protein name | Cyclic AMP-responsive element-binding protein 3-like protein 1 (cAMP-responsive element-binding protein 3-like protein 1) (Old astrocyte specifically-induced substance) (OASIS) [Cleaved into: Processed cyclic AMP-responsive element-binding protein 3-like protein 1] cAMP responsive element binding protein 3 like 1 |
Synonyms | OASIS PSEC0238 |
Description | FUNCTION: [Cyclic AMP-responsive element-binding protein 3-like protein 1]: Precursor of the transcription factor form (Processed cyclic AMP-responsive element-binding protein 3-like protein 1), which is embedded in the endoplasmic reticulum membrane with N-terminal DNA-binding and transcription activation domains oriented toward the cytosolic face of the membrane . In response to ER stress or DNA damage, transported to the Golgi, where it is cleaved in a site-specific manner by resident proteases S1P/MBTPS1 and S2P/MBTPS2. The released N-terminal cytosolic domain is translocated to the nucleus where it activates transcription of specific target genes involved in the cell-cycle progression inhibition . .; FUNCTION: [Processed cyclic AMP-responsive element-binding protein 3-like protein 1]: Transcription factor involved in cell type specific DNA damage and unfolded protein response (UPR). Binds the DNA consensus sequence 5'-GTGXGCXGC-3' . Plays a critical role in bone formation through the transcription of COL1A1, and possibly COL1A2, and the secretion of bone matrix proteins. Directly binds to the UPR element (UPRE)-like sequence in an osteoblast-specific COL1A1 promoter region and induces its transcription. Does not regulate COL1A1 in other tissues, such as skin (By similarity). Required to protect astrocytes from ER stress-induced cell death. In astrocytes, binds to the cAMP response element (CRE) of the BiP/HSPA5 promoter and participate in its transcriptional activation (By similarity). In astrocytes and osteoblasts, upon DNA damage, inhibits cell-cycle progression after G2/M phase by binding to promoters and activating transcription of genes encoding cell-cycle inhibitors, such as p21/CDKN1A (By similarity). Required for TGFB1 to activate genes involved in the assembly of collagen extracellular matrix . .; FUNCTION: (Microbial infection) May play a role in limiting virus spread by inhibiting proliferation of virus-infected cells. Upon infection with diverse DNA and RNA viruses, inhibits cell-cycle progression by binding to promoters and activating transcription of genes encoding cell-cycle inhibitors, such as p21/CDKN1A . . |
Accessions | ENST00000530518.1 ENST00000621158.5 [Q96BA8-1] E9PK33 Q96BA8 H0YEU7 ENST00000534787.1 |